Jenburkt Pharma Launches Covid-19 Drug Favipiravir At Rs 39 Per Tablet

Drug firm Jenburkt Pharmaceuticals on Friday said it has launched antiviral drug Favipiravir under the brand name 'Favivent' for the treatment of mild to moderate Covid-19 symptoms at a price of Rs 39 per tablet.

The tablet will be available in 200 mg strength in the form of a strip of 10 tablets, it added.

The drug will be manufactured at a pharmaceutical plant in Telangana with the highest safety and manufacturing protocols in place, Jenburkt Pharmaceuticals said in a statement.

On Thursday, pharma company Brinton Pharmaceuticals had said it will be selling Favipiravir under the brand name 'Faviton' at a maximum retail price of Rs 59 per tablet.

Pharma major Glenmark Pharmaceuticals is already selling Favipiravir under the brand name 'FabiFlu' at a price of Rs 75 per tablet.

ALSO READ: Cipla gets DCGI approval to sell Covid-19 drug favipiravir in India

Earlier this year, the (DCGI) had approved the use of Favipiravir -- an antiviral drug developed in Japan and commonly used for treating influenza -- for the treatment of mild to moderate cases of Covid-19 in India.

"Given the current scenario of grave health concerns and economic challenges surrounding Covid-19 in India, if we as a pharmaceutical company cannot make a significant positive difference to the society, our company's very existence is inconsequential," Jenburkt Pharmaceuticals Chairman and MDAshish U Bhuta said.

The company hopes that the easy accessibility and affordable price point of an effective treatment such as Favivent will offer Indian citizens a timely, much-needed therapeutic solution, he added.

Shares of Jenburkt Pharmaceuticals closed at Rs 391.90per scrip on BSE, down 1.05 per cent.

RECENT NEWS

JPMorgan Deploys AI Chatbot To Revolutionize Research And Productivity

JPMorgan has deployed an AI-based research analyst chatbot to enhance productivity among its workforce, with approximate... Read more

Private Equity And Banks: The Complex Web Of Leverage

Private equity has emerged as a significant force in the global financial landscape, driving substantial growth and inve... Read more

Financial Watchdog Highlights Unresolved Vulnerabilities In Shadow Banking Sector

The world’s leading financial stability watchdog has issued a warning about the unresolved vulnerabilities within the ... Read more

JPMorgan And Small Caps Lead Market Rally: A Sign Of Economic Optimism

In a week marked by strong financial performance, JPMorgan Chase & Co. reported a 25% rise in profits, and US small-... Read more

Big Banks Vs. Regional Banks: The Battle For Market Share

The financial industry is a competitive landscape where big banks and regional banks vie for market share. Each type of ... Read more

The Evolution Of Philanthropic Advisory Services In Private Banks

The landscape of philanthropic advisory services provided by private banks has undergone a significant transformation. T... Read more